You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

10 Results
Drug
Other Name(s): Tecvayli®
Jan 2025
Guidelines and Advice
Drug
Other Name(s): Trecondyv®
Jan 2025
Drug
Other Name(s): Tukysa™
Feb 2025
Regimen
Cancer Type:
Lung, 
Small Cell
Intent: Palliative
Feb 2025
Drug
Other Name(s): Jakavi®
Mar 2025
Regimen
Cancer Type:
Hematologic, 
Myeloproliferative Neoplasms (MPNs)
Intent: Palliative
Funding:
Exceptional Access Program
    ruxolitinib - For patients with intermediate to high risk symptomatic myelofibrosis, or patients with symptomatic splenomegaly, according to specific criteria
Exceptional Access Program
    ruxolitinib - For the treatment of patients with polycythemia vera according to criteria.
Mar 2025
Drug
Other Name(s): Orgovyx®
Updated
Apr 2025
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
ODB - General Benefit
    relugolix
Updated
Apr 2025